Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

[{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI\u2122-100 Advancing it Closer to First-in-Human Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Announces Pricing of $20.0 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditxt\u2019s (Nasdaq: ADTX) Adimune\u2122 Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI\u2122-100 in Preparation for Planned Psoriasis First-in-Human Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Aditxt

Aditxt
Developments
Full Screen View

Aditxt

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

13 News

13 News

DEVELOPMENTS

4 Drug(s) in Development

4 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Aditxt

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis Fi...

Details:

ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.

Lead Product(s): ADI-100

Therapeutic Area: Dermatology Product Name: ADI-100

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2022

ASK
US

Upload
your Pipeline Activity

Aditxt

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aditxt Announces Pricing of $20.0 Million Public Offering

Details:

The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.

Lead Product(s): Plasmid DNA-based Therapeutic

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering September 16, 2022

ASK
US

Upload
your Pipeline Activity

Aditxt

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Details:

ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.

Lead Product(s): ADI-100

Therapeutic Area: Immunology Product Name: ADI-100

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2022

ASK
US

Upload
your Pipeline Activity

Aditxt

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th

Details:

Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious diseases including Avigan.

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

Highest Development Status: Approved Product Type: Small molecule

Recipient: Cellvera

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 05, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY